Publicaciones en las que colabora con Tamara Fernandez Valle (13)
2024
-
Implication of nutrition in severity of symptoms and treatments in quality of life in Parkinson’s disease: a systematic review
Frontiers in Nutrition, Vol. 11
-
Plasma Neurofilament Light Chain: A Potential Biomarker for Neurological Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Biomedicines, Vol. 12, Núm. 7
-
Understanding the olfactory role in post-COVID cognitive and neuropsychiatric manifestations
Frontiers in Psychology, Vol. 15
2023
-
Clinical phenotype of postural orthostatic tachycardia associated with anti-adrenergic receptor antibodies
Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 120, Núm. 2, pp. 66-73
-
Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome
Journal of Translational Medicine, Vol. 21, Núm. 1
-
Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease
Journal of Neurology, Vol. 270, Núm. 8, pp. 3821-3829
2022
-
Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers
Parkinsonism and Related Disorders, Vol. 96, pp. 29-35
-
Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson's Disease
Journal of Parkinson's Disease, Vol. 12, Núm. 5, pp. 1633-1643
2021
-
Quantitative analysis of dysautonomia in patients with autonomic dysreflexia
Journal of Neurology, Vol. 268, Núm. 8, pp. 2985-2994
-
Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease
Annals of Neurology, Vol. 89, Núm. 1, pp. 165-176
2019
-
New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy
International Review of Neurobiology (Academic Press Inc.), pp. 281-295
2018
-
Anti-IgLON5 Disease Responsive to Immunotherapy: A Case Report with an Abnormal MRI
Movement Disorders Clinical Practice, Vol. 5, Núm. 6, pp. 653-656
-
Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting
Drugs and Therapy Perspectives, Vol. 34, Núm. 7, pp. 335-343